Oncotype DX® AR-V7 Nucleus Detect™
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
CommercialActive
Key Facts
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Commercial
Status
Active
Company
About Exact Sciences
Exact Sciences is a $20+ billion market cap leader in cancer diagnostics, driven by a mission to prevent, detect earlier, and guide treatment for cancer. Its success is anchored by the dominant Cologuard® colorectal cancer screening test and the globally recognized Oncotype DX® genomic test suite. The company's strategy focuses on expanding its integrated oncology portfolio, notably through the launch of its multi-cancer early detection test, CancerGuard™, and leveraging strategic partnerships like the one with Abbott for enhanced global scale. This positions Exact Sciences to address the full cancer care continuum from screening to treatment guidance.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |
| SYNC-T | Syncromune | Phase 2 |
| Gedatolisib | Celcuity | Phase 3 Planned |